GHRP-6 Side Effects: What Studies Report

GHRP-6 in the published record

GHRP-6 is a synthetic hexapeptide in the growth hormone secretagogue class. It acts at the growth hormone secretagogue receptor (GHS-R), the receptor also targeted by the stomach-derived hormone ghrelin, rather than at the growth hormone–releasing hormone receptor. That distinction matters for any discussion of unwanted effects, because ghrelin-receptor activation is not a growth-hormone-only event: the same receptor population sits in hypothalamic feeding circuits, in vagal and brainstem pathways, and in peripheral tissues. A 2015 Journal of Ethnopharmacology study illustrated the shared pathway when researchers reported that emoghrelin, an emodin derivative from Heshouwu, stimulated growth hormone secretion via activation of the ghrelin receptor (PMID 25446595).

Safety-relevant information about GHRP-6 in the literature comes from a handful of separate places rather than from one large clinical trial programme: short intravenous diagnostic tests in adult endocrinology, endocrine reference-value work, animal pharmacology on feeding and gastric function, formal repeated-dose toxicology of GHRP-6-based drug candidates, and scattered reports of non-endocrine actions. This page describes what those publications state. This page is for educational purposes only and is not medical advice; consult a licensed physician about any symptom, medication or health decision.

Appetite and feeding effects: What Studies Report

The most consistently studied pharmacological consequence of ghrelin-receptor activation is a change in feeding behaviour. A 2011 Behavioural Pharmacology study examined the behavioural satiety sequence in a genetic mouse model of obesity and reported the effects of ghrelin receptor ligands on that structured pattern of eating, grooming and resting (PMID 21897203). Work of this design matters for side-effect discussion because it separates a genuine increase in appetite drive from non-specific behavioural disruption: researchers looked at whether the normal sequence from feeding to satiety was preserved or distorted.

Central engagement of the same system has also been demonstrated by route-of-delivery work. A 2025 Endocrinology study reported that intranasal delivery of a ghrelin mimetic engaged the brain ghrelin signalling system in mice (PMID 39813130). The study is relevant to any reading of ghrelin-receptor pharmacology because it indicates that compounds acting at this receptor can reach and activate central circuits, which is where hunger signalling is integrated.

Neither of these papers assigned a frequency or severity grade to appetite change in humans. They describe receptor-level and behavioural pharmacology in rodents, and that is the limit of what they support.

Gastrointestinal and nausea-related findings: What Studies Report

Ghrelin-receptor signalling is closely tied to gastric motility and to brainstem nausea circuitry, and two animal papers in this set address that link from opposite directions. A 2018 Journal of Pharmacological Sciences study reported that enhancement of the ghrelin-signalling system by Rikkunshi-To attenuated teriparatide-induced pica in rats (PMID 29914799). Pica — the ingestion of non-nutritive material such as kaolin — is used in rodent research as a behavioural proxy for nausea, so the direction reported there was that stronger ghrelin signalling reduced a nausea-like behaviour rather than provoking one.

A 2019 General and Comparative Endocrinology study reported that ghrelin and electrical stimulation of the lateral hypothalamic area regulated the discharges of gastric distension neurons via the dorsal vagal complex in cisplatin-treated rats (PMID 30914266). That study maps the anatomical route by which ghrelin-receptor activation reaches gastric function: hypothalamus to dorsal vagal complex to stomach. Taken together, the two reports show that gastrointestinal sensation and motility are within the biological reach of ghrelin-receptor ligands, without establishing what proportion of exposed humans would notice a gut symptom.

Hormonal and biochemical parameters: What Studies Report

Because GHRP-6 sits in a receptor system with metabolic reach, several groups have probed what happens when the receptor is blocked rather than stimulated. A 2014 study in Arquivos Brasileiros de Endocrinologia e Metabologia examined the effects of the peptidic growth hormone secretagogue receptor antagonist [D-Lys3] on serum hormonal and biochemical parameters in a Wistar rat model (PMID 24863092). [D-Lys3]-GHRP-6 is a modified version of the GHRP-6 sequence used as a receptor antagonist, and the study is informative mainly because it shows that researchers treat circulating hormones and routine blood chemistry as the relevant readouts when this receptor is manipulated.

Growth hormone provocation itself is not unique to secretagogue peptides, which is worth noting when interpreting endocrine changes. A 2000 study in the Journal of Pediatric Endocrinology & Metabolism reported that acipimox, a nicotinic acid analogue, stimulated growth hormone secretion in short healthy prepubertal children (PMID 11085190). Several pharmacologically unrelated agents can raise growth hormone, so a rise in growth hormone after any stimulus is a shared endpoint rather than a compound-specific signature.

Human use in diagnostic testing: What Studies Report

The clearest human context for GHRP-6 in the published literature is diagnostic, not therapeutic. A 2000 Lancet report evaluated growth hormone–releasing hormone combined with growth hormone–releasing peptide-6 for diagnostic testing in growth hormone–deficient adults (PMID 11030292). In that setting the peptide was used as a short provocative stimulus under clinical supervision, with the aim of distinguishing deficient from sufficient growth hormone reserve, rather than as a repeated intervention.

That diagnostic role was carried forward into reference-value work. A 2009 article in the Netherlands Journal of Medicine, part VII of a series on establishing reference values for endocrine tests, addressed growth hormone deficiency testing (PMID 19581656). Papers of this kind exist to define what a normal stimulated response looks like, which is a prerequisite for interpreting any provocative test result. Neither publication was designed as an adverse-event study, so the human record summarised here describes single-occasion test use, not chronic administration.

Repeated-dose animal toxicology: What Studies Report

Formal toxicology on GHRP-6-based products exists in the preclinical literature. A 2025 paper in Regulatory Toxicology and Pharmacology described a subchronic safety assessment of CIGB-500, a GHRP-6-based drug candidate, in beagle dogs after repeated daily dose administration over 28 days (PMID 40024561). Subchronic studies of this design are the standard regulatory step before extended human exposure: they use a defined species, a fixed dosing interval and a fixed duration so that clinical observations and laboratory parameters can be compared against untreated controls.

The existence of such a study is itself part of the safety picture, because it shows that the compound class has been examined under structured toxicology conditions rather than only in acute pharmacology experiments. It does not, however, translate into human adverse-event rates, and the published abstract scope is limited to the dog model and the 28-day window.

Non-endocrine and off-target findings: What Studies Report

Some reported actions of GHRP-6 sit outside the growth hormone axis entirely. A 2017 Vaccine study reported that growth hormone releasing peptide-6 enhanced antibody titres against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus) (PMID 28893476). An immunological effect of this kind is a reminder that receptor systems rarely produce one isolated outcome, and that immune endpoints have been measured in this compound class across several species.

The receptor has also been used as a design element in unrelated drug chemistry. A 2025 Biochimie paper reported that novel chimeric peptides based on endomorphins and a ghrelin receptor antagonist produced supraspinal antinociceptive effects with reduced acute tolerance in mice (PMID 39147011). That work concerns pain pharmacology rather than GHRP-6 itself, but it demonstrates that ghrelin-receptor ligands interact with central nervous system pathways beyond appetite and growth hormone release.

Reported observation domains at a glance

What this literature does not establish

Several things commonly assumed about GHRP-6 tolerability are not answered by the publications summarised above:

• Frequency and severity of specific complaints. None of these papers was an adverse-event surveillance study in humans, so no incidence figures follow from them.
• Long-term human exposure. The human context described here was short diagnostic provocative testing in adults (PMID 11030292), not extended repeated dosing.
• Cross-species translation. The feeding, gastric and toxicology findings were generated in mice, rats and dogs, and species differences in ghrelin-receptor pharmacology are not resolved by these reports.
• Interactions and comorbidities. The verified record does not describe interaction studies with other medications or outcomes in specific patient populations.

Regulatory context

GHRP-6 is not an approved medicine in the United States, and material sold under research-use-only labelling is not manufactured, tested or released for human administration. The peptide's documented human appearance in the literature is as a short-acting provocative agent within endocrine testing protocols (PMID 11030292), alongside reference-value work on growth hormone deficiency testing (PMID 19581656). Any symptom or health question belongs with a licensed clinician who can evaluate the individual case.

How this page fits with the GHRP-6 course

This page is limited to the safety and adverse-event literature: what was measured, in which species, and what remains unmeasured. The PeptideU GHRP-6 course covers the upstream material instead — receptor biology, how secretagogues differ from growth hormone–releasing hormone analogues, how provocative testing is structured, and how to read a pharmacology abstract. Readers looking for mechanism and study-design teaching will find it there; readers looking for the reported-effects record are in the right place here.

References

• GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults (Lancet, 2000)
• Establishment of reference values for endocrine tests. Part VII: growth hormone deficiency (The Netherlands Journal of Medicine, 2009)
• Acipimox, a nicotinic acid analog, stimulates growth hormone secretion in short healthy prepubertal children (Journal of Pediatric Endocrinology & Metabolism, 2000)
• Behavioral satiety sequence in a genetic mouse model of obesity: effects of ghrelin receptor ligands (Behavioural Pharmacology, 2011)
• Enhancement of ghrelin-signaling system by Rikkunshi-To attenuates teriparatide-induced pica in rats (Journal of Pharmacological Sciences, 2018)
• Ghrelin and electrical stimulating the lateral hypothalamus area regulated the discharges of gastric distention neurons via the dorsal vagal complex in cisplatin-treated rats (General and Comparative Endocrinology, 2019)
• Effects of peptidic growth hormone secretagogue receptor (GHS-R) antagonist [D-Lys3] on some of serum hormonal and biochemical parameters in Wistar rat model (Arquivos Brasileiros de Endocrinologia e Metabologia, 2014)
• Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days (Regulatory Toxicology and Pharmacology, 2025)
• Intranasal Delivery of a Ghrelin Mimetic Engages the Brain Ghrelin Signaling System in Mice (Endocrinology, 2025)
• Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus) (Vaccine, 2017)
• Emoghrelin, a unique emodin derivative in Heshouwu, stimulates growth hormone secretion via activation of the ghrelin receptor (Journal of Ethnopharmacology, 2015)
• Novel chimeric peptides based on endomorphins and ghrelin receptor antagonist produced supraspinal antinociceptive effects with reduced acute tolerance in mice (Biochimie, 2025)